Assessment of differences in clinical consequences between rituximab and interferon recipients in multiple sclerosis patients after recovery from COVID-19
Compared to interferon, rituximab was linked to worse clinical outcomes in MS patients after COVID-19 recovery, indicating that its use during pandemics should be used with caution.
Authors
- Seyyed Mahdi Hosseini Sarkhosh (ORCID: https://orcid.org/0000-0001-7760-9074)
- Sahar Mehranfar (ORCID: https://orcid.org/0000-0001-7831-7102)
- Zahra Farrokhi (ORCID: https://orcid.org/0009-0007-5699-1017)
- Saleh Behzadi (ORCID: https://orcid.org/0000-0001-7912-6914)
- Nazanin Moeini
- Arash Musa Al-Rezai Aghdam
Institutions
- Arak University of Medical Sciences (IR)
- Urmia University (IR)
- Urmia University of Medical Sciences (IR)
- Shahid Beheshti University of Medical Sciences (IR)
- Rafsanjan University of Medical Sciences (IR)
Publication Details
- Journal
- IBRO Neuroscience Reports
- Published
- 2025-10-18
- DOI
- https://doi.org/10.1016/j.ibneur.2025.08.015
- Primary Topic
- Multiple Sclerosis Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00